BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind (MNKD)MannKindPartnership

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind

Related news

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

ALGSAligos Therapeutics2026-07-06 20:05 EST

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

MLYSMineralys Therapeutics2026-06-03 10:00 EST

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

SENSSenseonics2026-09-14 11:00 EST

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-09-09 10:30 EST

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

Stock data

Close
3.58 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States